Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion type Assertion NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_head.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion description "[The clinical relevance of these findings is strongly supported since TCD-717 has recently entered Phase I clinical trials against solid tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_provenance.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion evidence source_evidence_literature NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_provenance.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion SIO_000772 23762272 NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_provenance.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion wasDerivedFrom befree-20140225 NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_provenance.
- NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_assertion wasGeneratedBy ECO_0000203 NP704373.RApWSB1igN2758Az87sVZ59PwBh4bE3i2fVkC6YgGptvg130_provenance.